Effect of Shufeng Jiedu capsules as a broad-spectrum antibacterial
- PMID: 26875500
- DOI: 10.5582/bst.2015.01172
Effect of Shufeng Jiedu capsules as a broad-spectrum antibacterial
Abstract
This study sought to investigate the broad-spectrum antibacterial action of an alternative medicine, Shufeng Jiedu capsules (SFJDC). Antibacterial testing was performed to determine whether SFJDC had broad-spectrum antibacterial action in vitro, and testing was performed to verify whether SFJDC prevented death due to a Streptococcus or Staphylococcus aureus infection in mice. Results of antibacterial testing suggested that SFJDC are a broad-spectrum antibacterial and that SFJDC are superior to Lianhua Qingwen capsules as a broad-spectrum antibacterial. Results of testing revealed that SFJDC lowered the mortality rate, it reduced mortality, it increased average survival time, and it increased the lifespan of mice dying due to a Staphylococcus aureus or Streptococcus infection. Thus, SFJDC could become a complement to broad-spectrum antimicrobials in clinical settings.
Similar articles
-
Polysaccharides isolated from shufeng jiedu capsules by cross-flow ultrafiltration show anti-inflammatory effects on LPS-stimulated RAW264.7 cells and zebrafish inflammatory models.J Ethnopharmacol. 2025 May 28;348:119817. doi: 10.1016/j.jep.2025.119817. Epub 2025 Apr 17. J Ethnopharmacol. 2025. PMID: 40250639
-
Shufeng Jiedu Capsule and its active ingredients induce apoptosis, inhibit migration and invasion, and enhances doxorubicin therapeutic efficacy in hepatocellular carcinoma.Biomed Pharmacother. 2018 Mar;99:921-930. doi: 10.1016/j.biopha.2018.01.163. Epub 2018 Feb 20. Biomed Pharmacother. 2018. PMID: 29710492
-
Shufeng Jiedu, a promising herbal therapy for moderate COVID-19:Antiviral and anti-inflammatory properties, pathways of bioactive compounds, and a clinical real-world pragmatic study.Phytomedicine. 2021 May;85:153390. doi: 10.1016/j.phymed.2020.153390. Epub 2020 Oct 22. Phytomedicine. 2021. PMID: 33158717 Free PMC article. Clinical Trial.
-
Potential therapeutic effect of Shufeng Jiedu capsule and its major herbs on coronavirus disease 2019 (COVID-19): A review.Drug Discov Ther. 2022 Jan 15;15(6):289-299. doi: 10.5582/ddt.2021.01099. Epub 2021 Dec 30. Drug Discov Ther. 2022. PMID: 34980761 Review.
-
Is there any rationale for treatment of Staphylococcus aureus infections with antimicrobials that are determined to be ineffective in vitro?Clin Microbiol Infect. 2011 Aug;17(8):1142-7. doi: 10.1111/j.1469-0691.2011.03549.x. Epub 2011 Jun 14. Clin Microbiol Infect. 2011. PMID: 21672081 Review.
Cited by
-
Chinese Patent Medicine Shufeng Jiedu Capsules as an Adjuvant Therapy for Community-Acquired Pneumonia: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.Front Pharmacol. 2022 Jul 4;13:923395. doi: 10.3389/fphar.2022.923395. eCollection 2022. Front Pharmacol. 2022. PMID: 35860018 Free PMC article.
-
Chinese patent herbal medicine (Shufeng Jiedu capsule) for acute upper respiratory tract infections: A systematic review and meta-analysis.Integr Med Res. 2021 Sep;10(3):100726. doi: 10.1016/j.imr.2021.100726. Epub 2021 Apr 2. Integr Med Res. 2021. PMID: 33996460 Free PMC article. Review.
-
Shufeng Jiedu Granule against mild COVID-19: Protocol of the randomized, double-blind, placebo-controlled, multi-center heal-COVID phase III study.Chin Herb Med. 2025 Apr 24;17(3):601-608. doi: 10.1016/j.chmed.2025.04.005. eCollection 2025 Jul. Chin Herb Med. 2025. PMID: 40734912 Free PMC article.
-
Treating acute exacerbations of COPD with Chinese herbal medicine to aid antibiotic use reduction (Excalibur): a randomised double-blind, placebo-controlled feasibility trial.Front Pharmacol. 2023 Sep 25;14:1221905. doi: 10.3389/fphar.2023.1221905. eCollection 2023. Front Pharmacol. 2023. PMID: 37818189 Free PMC article.
-
Shufeng Jiedu capsule for acute exacerbation of chronic obstructive pulmonary disease: a protocol of multicentre, randomised, double-blind, placebo-controlled trial.BMJ Open. 2023 Sep 29;13(9):e070864. doi: 10.1136/bmjopen-2022-070864. BMJ Open. 2023. PMID: 37775286 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical